NEWS

ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally

ImmunityBio
Shares of ImmunityBio Inc. rose sharply midday Thursday as the commercial-stage immunotherapy company reported record preliminary first-quarter 2026 net product revenue of approximately $44.2 million from its flagship bladder cancer therapy ANKTIVA, marking a 168% increase from the same period last year and underscoring accelerating commercial traction despite a recent FDA warning on promotional materials.
More news

Pages

  • Prev
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next